Evidence map›Paper›PMID 30497281›Full record

ArticleAntiviral chemistry & chemotherapy

Xanthine-based acyclic nucleoside phosphonates with potent antiviral activity against varicella-zoster virus and human cytomegalovirus.

Ondřej Baszczyňski, Martin Maxmilian Kaiser, Michal Česnek, Petra Břehová, Petr Jansa, Eliška Procházková, Martin Dračínský, Robert Snoeck, Graciela Andrei, Zlatko Janeba

Open access · hybridAbstract read
In one paragraph

Article in Antiviral chemistry & chemotherapy. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Ondřej Baszczyňski1 Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Prague, Czech Republic.
Martin Maxmilian Kaiser1 Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Prague, Czech Republic.
Michal Česnek1 Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Prague, Czech Republic.
Petra Břehová1 Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Prague, Czech Republic.
Petr Jansa1 Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Prague, Czech Republic.
Eliška Procházková1 Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Prague, Czech Republic.
Martin Dračínský1 Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Prague, Czech Republic.
Robert Snoeck2 Laboratory of Virology and Chemotheraphy, Rega Institute, Leuven, Belgium.
Graciela Andrei2 Laboratory of Virology and Chemotheraphy, Rega Institute, Leuven, Belgium.
Zlatko Janeba1 Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Prague, Czech Republic.ORCID https://orcid.org/0000-0003-4654-679X
Czech Academy of Sciences, Institute of Organic Chemistry and Biochemistry · CZRega Institute for Medical Research · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

While noncanonic xanthine nucleotides XMP/dXMP play an important role in balancing and maintaining intracellular purine nucleotide pool as well as in potential mutagenesis, surprisingly, acyclic nucleoside phosphonates bearing a xanthine nucleobase have not been studied so far for their antiviral properties. Herein, we report the synthesis of a series of xanthine-based acyclic nucleoside phosphonates and evaluation of their activity against a wide range of DNA and RNA viruses. Two acyclic nucleoside phosphonates within the series, namely 9-[2-(phosphonomethoxy)ethyl]xanthine (PMEX) and 9-[3-hydroxy-2-(phosphonomethoxy)propyl]xanthine (HPMPX), were shown to possess activity against several human herpesviruses. The most potent compound was PMEX, a xanthine analogue of adefovir (PMEA). PMEX exhibited a single digit µM activity against VZV (EC

Indexed as

Antiviral AgentsCytomegalovirusDose-Response Relationship, DrugHerpesvirus 3, HumanHumansMicrobial Sensitivity TestsMolecular StructureNucleosidesOrganophosphonatesStructure-Activity RelationshipXanthineAntiviral AgentsNucleosidesOrganophosphonatesXanthineAcyclic nucleoside phosphonatesantiviralHCMVPMEXVZVxanthine

Identifiers

PMID30497281
PMCPMC6287304
OpenAlexW2902320275

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.